Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Krzysztof Selmaj et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Ludwig Kappos et al.|New England Journal of Medicine|2016Cited by 1.9k
Restoring immune tolerance in neuromyelitis opticaAmit Bar‐Or, Kevin C. O’Connor, Jacinta M. Behne et al.|Neurology Neuroimmunology & Neuroinflammation|2016Cited by 57
Challenges and opportunities in designing clinical trials for neuromyelitis opticaBrian G. Weinshenker, Michael R. Yeaman, Gerard Barron et al.|Neurology|2015Cited by 46
Restoring immune tolerance in neuromyelitis opticaKevin C. O’Connor, Amit Bar‐Or, Jacinta M. Behne et al.|Neurology Neuroimmunology & Neuroinflammation|2016Cited by 42